Format

Send to

Choose Destination
Cancer Invest. 2009 Jan;27(1):13-6. doi: 10.1080/07357900802484944.

Treating in the dark: unanswered questions on costs and benefits of late line therapy for metastatic breast cancer.

Author information

1
Department of Hematology-Oncology, University of North Carolina/Lineberger Cancer Center, Chapel Hill, North Carolina, USA. carey anders@med.unc.edu
PMID:
19160108
DOI:
10.1080/07357900802484944
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center